

Special Issue

Hepatocellular Carcinoma: From Screening to Treatment, a Never-Ending Story

Message from the Guest Editor

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, with a global incidence exceeding 84,000 cases annually. It ranks as the sixth most common cancer and the fourth leading cause of cancer-related death worldwide. Given its high incidence and significant mortality rate, timely screening and treatment are crucial. Screening for HCC is recommended for high-risk patients, such as those with cirrhosis or chronic hepatitis B and C. This practice has been associated with improved early detection, increased receipt of curative treatments, and better survival rates. Emerging biomarkers and advanced imaging techniques are enhancing the screening process for HCC. Treatment options for HCC have evolved significantly over the years, particularly with the advent of immunotherapy as a systemic treatment. This Special Issue highlights recent advancements in the screening and various treatment options for HCC.

Guest Editor

Prof. Dr. Kelvin K. NG

Department of Surgery, Prince of Wales Hospital, Shatin, N.T., Hong Kong, China

Deadline for manuscript submissions

closed (13 March 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/213887

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)